

Trastuzumab emtansine (solution)

Cat. No.:	HY-P9921A	
CAS No.:	1018448-65-1	
Target:	Antibody-Drug Conjugates (ADCs); EGFR	
Pathway:	Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK	Trastuzumab emtansine (solution)
Storage:	Powder -20°C 3 years	

* The compound is unstable in solutions, freshly prepared is recommended.

BIOLOGICAL ACTIVITY

Description

Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1 (derivative of maytansine). Trastuzumab emtansine can be used for the research of advanced breast cancer^{[1][2]}.

CUSTOMER VALIDATION

- Adv Sci (Weinh). 2024 Jan 25:e2306309.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Verma S, et, al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012 Nov 8;367(19):1783-91.

[2]. Menderes G, et, al. Superior in vitro and in vivo activity of trastuzumab-emtansine (T-DM1) in comparison to trastuzumab, pertuzumab and their combination in epithelial ovarian carcinoma with high HER2/neu expression. Gynecol Oncol. 2017 Oct;147(1):145-152.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA